pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,103 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1172Endpoints888BioPharma Dive342BioSpace307Fierce Biotech290onclive165raps104globenewswire health73
therapy area
allOncology7574Rare Disease1867Cardiology1741Immunology1478Hematology1319Vaccines1197Pulmonology
  • Oura and Whoop add in-app virtual doctor visits, moving wearable data toward clinical use
    Wearable makers Oura and Whoop announced that users will soon be able to connect with doctors through their apps, allowing virtual consultations when a device flags a health concern. The new featu…
    STAT · 3mo agoNeutral↗ source
  • Trump-suppressed alcohol health study released, finds low-level drinking may raise disease risk
    A federal study on alcohol's health effects, commissioned by SAMHSA in 2023 to inform U.S. dietary guidelines, has finally been published in a scientific journal after being withheld by the Trump a…
    STAT · 3mo agoRegulatoryNegative↗ source
← prev
page 92 of 125
next →
fda recalls67
fda medwatch60
fda press38
1158
Psychiatry & CNS866
Ophthalmology494
Pain478
Endocrinology & Metabolism473
Infectious Disease444
  • Endpoints launches nominations for its 2026 Women in Biopharma project
    Endpoints announced that nominations are now open for its eighth annual Women in Biopharma initiative, which highlights contributions of women in the industry. The program, scheduled for 2026, see…
    Endpoints · 3mo agoPositive↗ source
  • NIH staff say leadership ignored dissent letter a year after Bethesda Declaration
    A new report released on the one‑year anniversary of the Bethesda Declaration says NIH leadership has largely ignored the concerns raised by staff in their open letter of dissent. The report, titl…
    STAT · 3mo agoNegative↗ source
  • STAT chooses to keep health care as two words despite AP stylebook shift
    The Associated Press updated its style guide in April, merging health care into the single word healthcare. The change sparked discussion among journalists and readers. At STAT, the editorial staf…
    STAT · 3mo agoNeutral↗ source
  • Roche commits $700 million to co-develop Nurix's BTK-degrading drug bexobrutideg
    Roche announced a partnership with Nurix Therapeutics to co-develop a protein-degrading therapy called bexobrutideg, which targets the BTK enzyme. Under the agreement, Roche will pay $700 million…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Lilly’s retatrutide data at ADA 2026 underscores its lead in obesity drug market
    The American Diabetes Association’s 2026 meeting highlighted a wave of new weight‑loss drug data as companies vie for a slice of a market dominated by Eli Lilly and Novo Nordisk. Lilly presented r…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • J&J to buy Firefly Bio for $1 billion to boost KRAS inhibitor program
    J&J announced Monday it will acquire biotech startup Firefly Bio for $1 billion, aiming to broaden its KRAS inhibitor portfolio. The move follows recent data from Revolution Medicines showing a KR…
    STAT · 3mo agoDealPositive↗ source
  • Tango to launch Phase 3 trial in pancreatic cancer after promising combo results
    Tango announced plans to begin a Phase 3 trial testing a combination therapy for pancreatic cancer. The decision follows data presented at the American Society of Clinical Oncology meeting, where…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Roche to pay $700M upfront to Nurix for BTK degrader collaboration, deal up to $2.3B
    Roche announced a collaboration with Nurix Therapeutics to develop a BTK degrader for B cell malignancies. Roche will provide $700 million upfront, and the agreement could be worth up to $2.3 bill…
    Endpoints · 3mo agoDealPositive↗ source
  • Financing gaps keep $2 million gene therapies out of reach for many patients
    William Padula argues that the United States lacks the financial infrastructure to deliver ultra‑expensive gene therapies, even though they can cure diseases with a single dose. He notes that treat…
    STAT · 3mo agoNegative↗ source
  • Lilly shares safety data on next-gen obesity drug retatrutide; Revolution Medicines reports strong pancreatic cancer results
    Lilly provided new data that detail the safety and tolerability profile of its next-generation obesity therapy, retatrutide. The information adds to the growing body of evidence supporting the drug…
    STAT · 3mo agoPositive readoutPositive↗ source
  • AstraZeneca’s GLP-1 obesity pill shows 10.5% average weight loss after six months in Phase 2 trial
    AstraZeneca reported data from its Phase 2 study of a GLP-1 based oral obesity treatment. The trial showed participants lost an average of 10.5% of body weight after six months of therapy. The re…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • AstraZeneca’s oral GLP-1 candidate elecoglipron cuts weight 11% in Phase 2 obesity trial
    A Phase 2 study (VISTA) of AstraZeneca’s oral GLP‑1 molecule elecoglipron in people with obesity showed an average weight loss of 11.2 % after 36 weeks, according to data presented at the American…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Incyte to acquire Vega Therapeutics for up to $2 billion, securing late-stage von Willebrand disease drug
    Incyte announced it will purchase Vega Therapeutics, a unit of Star Therapeutics, for $1.25 billion in cash with the possibility of receiving up to $750 million more if future sales targets are met…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • J&J to acquire Firefly Bio for $1 billion, adding degrader-antibody conjugate technology
    J&J announced it will acquire biotech startup Firefly Bio in an all‑cash transaction valued at $1 billion. The deal gives J&J access to Firefly’s degrader‑antibody conjugate platform, which blends…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Treeline Biosciences to go public via reverse merger with Standard BioTools, securing runway to 2029
    Treeline Biosciences announced that it will become a publicly traded company through a reverse merger with Standard BioTools. The transaction is expected to list the combined entity on a U.S. excha…
    Endpoints · 3mo agoDealPositive↗ source
  • J&J to acquire Firefly Bio for $1 billion, boosting its KRAS-focused antibody-degrader program
    Johnson & Johnson announced it will purchase Firefly Bio, a preclinical biotech, for $1 billion in cash. Firefly Bio is developing degrader antibody conjugates that aim to target KRAS-driven cance…
    Endpoints · 3mo agoDealPositive↗ source
  • Incyte agrees to acquire Vega Therapeutics for $1.25 billion upfront
    Incyte announced it will purchase Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction that includes an upfront payment of $1.25 billion. The acquisition gives Incyte control of…
    Endpoints · 3mo agoDealNeutral↗ source
  • Congo Ebola frontline health workers face low pay and exhaustion amid outbreak
    Dr. Richard Lokudu, medical director of Mongbwalu General Referral Hospital, says he and his colleagues are receiving almost no compensation while treating patients in the current Ebola outbreak.…
    STAT · 3mo agoNegative↗ source
  • City Therapeutics secures $99.5 million to advance RNAi drugs targeting clotting disorder and Stargardt disease
    City Therapeutics, a young biotech focused on RNA interference therapies, announced it has raised $99.5 million to support further development of its pipeline. The funding will back its lead candid…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Incyte CEO frames $2 billion Vega acquisition as key to post-Jakafi strategy
    Incyte's chief executive Bill Meury said the company’s recent $2 billion purchase of Vega is intended to expand its blood‑disorder pipeline beyond the already‑approved Jakafi. Meury, who has previ…
    Endpoints · 3mo agoDealPositive↗ source
  • City Therapeutics raises $99.5 million to advance three RNAi drug candidates
    City Therapeutics, a next‑generation RNA interference startup founded by former Alnylam executives, announced it has secured $99.5 million in financing. The capital will be used to move its first…
    Endpoints · 3mo agoDealPositive↗ source
  • GoHealth files for Chapter 11 bankruptcy as Medicare Advantage insurers retreat
    GoHealth, a health‑insurance marketplace that serves seniors, voluntarily filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court. The filing follows a period of volatility in the Medicare Ad…
    Endpoints · 3mo agoNegative↗ source
  • Tango Therapeutics reports strong early response with vopimetostat plus daraxonrasib in pancreatic cancer trial
    Tango Therapeutics announced that its experimental epigenetic drug vopimetostat, when combined with Revolution Medicines' KRAS inhibitor daraxonrasib, produced high response rates in a small pancre…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source